title: Late onset post-transfusion hepatitis E developing during chemotherapy for acute promyelocytic leukemia.
abstract: We herein report the case of a leukemia patient who developed hepatitis E seven months after undergoing a transfusion with contaminated blood products. The latency period in this case was significantly longer than that of typical hepatitis E. Recently, chronic infection with hepatitis E virus (HEV) genotype 3 has been reported in immunocompromised patients. There is a possibility that our patient was unable to eliminate the virus due to immunosuppression following chemotherapy and the administration of steroids. The prevalence of HEV in healthy Japanese individuals is relatively high and constitutes a critical source of infection via transfusion. Hepatitis E is an important post-transfusion infection, and immunocompromised patients may exhibit a long latency period before developing the disease.
authors: Department of Hematology, Endocrinology and Metabolism Niigata University Faculty of Medicine, Japan.
authors: Kyoko
authors: K
authors: Fuse
authors: Yuichi
authors: Y
authors: Matsuyama
authors: Masato
authors: M
authors: Moriyama
authors: Shukuko
authors: S
authors: Miyakoshi
authors: Yasuhiko
authors: Y
authors: Shibasaki
authors: Jun
authors: J
authors: Takizawa
authors: Tatsuo
authors: T
authors: Furukawa
authors: Ichiro
authors: I
authors: Fuse
authors: Hiro
authors: H
authors: Matsumura
authors: Shigeharu
authors: S
authors: Uchida
authors: Yoshifumi
authors: Y
authors: Takahashi
authors: Kenya
authors: K
authors: Kamimura
authors: Hiroyuki
authors: H
authors: Abe
authors: Takeshi
authors: T
authors: Suda
authors: Yutaka
authors: Y
authors: Aoyagi
authors: Hirohito
authors: H
authors: Sone
authors: Masayoshi
authors: M
authors: Masuko
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D016751:Hepatitis E / Q000097:blood / Q000175:diagnosis / Q000209:etiology*; D016752:Hepatitis E virus / Q000302:isolation & purification; D006801:Humans; D016867:Immunocompromised Host; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced* / Q000188:drug therapy*; D065227:Transfusion Reaction; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents